1.
Rev Pneumol Clin
; 56(3): 200-3, 2000 Jun.
Artigo
em Francês
| MEDLINE
| ID: mdl-10880946
RESUMO
From January 1990 to November 1994, 23 patients with advanced pretreated lung carcinoma were enrolled into a phase II trial to test a new nitrosourea, cystemustine, given every 2 weeks at the dose of 60 mg/m(2) in a 15-minute IV infusion. All eligible patients were considered evaluable for response and toxicity (WHO criteria).